Empagliflozin is an SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. It works by helping the kidneys remove excess glucose through the urine while also promoting sodium and fluid excretion.
Benefits:
- Helps lower blood glucose levels
- Can support weight loss through urinary glucose loss
- Reduces the risk of hospitalisation for heart failure
- Provides kidney-protective benefits in appropriate patients
- May help reduce cardiovascular risk
Potential Side Effects:
- Increased urination and thirst
- Genital yeast infections or urinary tract infections
- Dehydration or dizziness
- Rarely, diabetic ketoacidosis





